BioMarin Pharmaceutical Inc. Acquires Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. has entered into an Agreement and Plan of Merger with Amicus Therapeutics, Inc. for a cash acquisition of $14.50 per share. The merger, expected to close in the second quarter of 2026, will result in Amicus becoming a wholly owned subsidiary of BioMarin. This acquisition aims to accelerate BioMarin's revenue growth, strengthen its financial outlook, and diversify its rare disease product portfolio. BioMarin plans to finance the transaction through a combination of debt financing, including a $3.65 billion bridge loan facility, and potentially capital markets transactions. The deal is subject to customary closing conditions, including regulatory approvals and Amicus stockholder approval. The agreement includes provisions for termination fees under certain circumstances, with Amicus potentially owing BioMarin $175 million if the deal is terminated under specific conditions, such as Amicus accepting a superior offer.